Article
Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
British journal of pharmacology - 1 Jun 2004
Thomas Dierk, Hammerling Bettina C, Wu Kezhong, Wimmer Anna-Britt, Ficker Eckhard K, Kirsch Glenn E, Kochan Mary C, Wible Barbara A, Scholz Eberhard P, Zitron Edgar, Kathöfer Sven, Kreye Volker A W, Katus Hugo A, Schoels Wolfgang, Karle Christoph A, Kiehn Johann
Abstract excerpt
1 The topoisomerase II inhibitor amsacrine is used in the treatment of acute myelogenous leukemia. Although most anticancer drugs are believed not to cause acquired long QT syndrome (LQTS), concerns have been raised by reports of QT interval prolongation, ventricular fibrillation and death associated with amsacrine treatment. Since blockade of cardiac human ether-a-go-go-related gene (HERG) potassium currents is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.